For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$1,150.99
Thesis
Eli Lilly markets the tirzepatide products Mounjaro and Zepbound, which target type 2 diabetes and obesity. As a diversified pharmaceutical company, it also advances an oral GLP-1 pipeline alongside its injectable franchise.
Catalysts
- Oral GLP-1 candidate clinical readouts
- Manufacturing capacity expansion for tirzepatide
- Label expansions for Mounjaro and Zepbound
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Sep 22Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 master protocol trial NCT07165028 (SYNERGY-Outcomes) evaluating multiple agents in MASLD; recruiting status.
- Sep 22Trial initiationClinicalTrials.gov
Phase 3 trial NCT07241390 of orforglipron for CV outcomes in ASCVD/CKD patients begins recruiting.
- Sep 22Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial of Brenipatide in Alcohol Use Disorder (NCT07219953, recruiting).
- Sep 22Trial initiationClinicalTrials.gov
Phase 2 trial NCT07589595 (TRAILBLAZER-ALZ 7) of donanemab in early cognitive decline updated to recruiting status.
- Sep 22Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial NCT07794579 of orforglipron in overweight participants at risk of obesity complications.
- Sep 22OtherClinicalTrials.gov
Phase 3 TRAILBLAZER-ALZ 5 trial of donanemab for early Alzheimer's updated to ACTIVE_NOT_RECRUITING on 2026-09-22.
- Sep 22Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 3 trial NCT07282600 of Eloralintide (LY3841136) in obesity/overweight with Type 2 diabetes; status recruiting.
- Sep 22Trial initiationClinicalTrials.gov
Phase 3 trial NCT07369011 of Eloralintide (LY3841136) in obstructive sleep apnea and obesity/overweight now recruiting.